Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Lymphoma (follicular non-Hodgkin's) - rituximab: review decision - March 2011  information

Appendix A: decision paper presented to the Institute's Guidance Executive (PDF 84 KB)

Lymphoma (follicular non-Hodgkin's) - rituximab: review proposal - January 2011 information

Appendix A: provisional matrix of stakeholders (MSWord 58 KB)

Appendix B: proposal paper presented to NICE's Guidance Executive (PDF 114 KB)

Follicular lymphoma - rituximab: final appraisal determination  information

Follicular lymphoma - rituximab: final appraisal determination (PDF 95 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 57 KB)

Consultee and commentator comments on the ACD

Joint comment from British Society for Haematology and the Royal College of Physicians/Royal College of Pathologists Intercollegiate Committee in Haematology (PDF 25 KB)

Joint comment from NCRI Lymphoma Clinical Studies Group, Royal College of Physicians, the Royal College of Radiologists, the Joint Collegiate Council for Oncology and the Association of Cancer Physicians (PDF 49 KB)

Roche (PDF 1.16 MB)

Royal College of Nursing (PDF 22 KB)

Royal College of Pathologists (PDF 110 KB)

Welsh Assembly Government (PDF 63 KB)

Hancock (PDF 13 KB)

Follicular lymphoma - rituximab: Appraisal consultation 

Follicular lymphoma - rituximab: appraisal consultation document information

Follicular lymphoma - rituximab: Evaluation report

Expert written personal statements

Hancock (PDF 81 KB)

Hamblin (PDF 19 KB)

Manufacturer submission

Roche response to clarification letter (PDF 7.31 MB)

Clarification letter from NICE (PDF 1.73 MB)

Roche Products Limited (PDF 1007 KB)

Lymphoma Association (PDF 86 KB)

EMEA documents

EMEA letter (PDF 920 KB)

EMEA scientific discussion (PDF 1.53 MB)

BCSH Guidelines (PDF 2.94 MB)

Evidence Review Group report

Supplemental Evidence Review Group report (PDF 121 KB)

Lymphoma (follicular non-Hodgkin's) - rituximab: evidence review group report (PDF 654 KB)

Pre-meeting briefing (PDF 154 KB)

Response to consultee and commentators comments on the draft Matrix and Scope (PDF 59 KB)

Follicular lymphoma - rituximab: final scope (PDF 37 KB)

Letter to consultees and commentators (MSWord 30 KB)